Line 62: | Line 62: | ||
<h3><a id="EA" href="#EAback">Environmental Analysis</a></h3> | <h3><a id="EA" href="#EAback">Environmental Analysis</a></h3> | ||
<p> | <p> | ||
− | < | + | <h5><b>Macroeconomic:</b></h5> |
<ul><li><b>Political & Legal:</b></li></ul> | <ul><li><b>Political & Legal:</b></li></ul> | ||
Recently, the relevant Egyptian Health authorities backed by the government pushed for a clinical research management bill that legalizes and controls the implementation of clinical trials in the country (Gomaa, 2020). This shows an increasing interest on the government’s end in supporting the research and development of novel therapeutics created within the country. The country’s interest in COVID-19 therapeutics is also evident in the promptness of action in securing a production license of Remdesivir in June just weeks after the drug received its Emergency Usage Authorization from the FDA (Al Tawy, 2020). However, support for genetic engineering endeavors is not yet available as a bill for the regulation of GE research remains in parliament debate (Badr, 2015). | Recently, the relevant Egyptian Health authorities backed by the government pushed for a clinical research management bill that legalizes and controls the implementation of clinical trials in the country (Gomaa, 2020). This shows an increasing interest on the government’s end in supporting the research and development of novel therapeutics created within the country. The country’s interest in COVID-19 therapeutics is also evident in the promptness of action in securing a production license of Remdesivir in June just weeks after the drug received its Emergency Usage Authorization from the FDA (Al Tawy, 2020). However, support for genetic engineering endeavors is not yet available as a bill for the regulation of GE research remains in parliament debate (Badr, 2015). |
Revision as of 14:15, 25 October 2020
ENTREPRENEURSHIP
- Executive Summary
- Team
- Market
- Segmentation
- Stakeholder mapping
- Competitor analysis
- Unique Value Proposition (UVP)
- Possibility & Scalability
- Cost structure
- Funding
- Success Metrics
- Funding milestones
- Impact
- Appendix
Executive Summary
We are adopting a B2B business model targeting physicians in military hospitals and directly distributing to them. Our target market strategy: concentrated marketing. Our unique value proposition: Our therapy is specifically designed & tailored for the treatment of COVID-19; It is not a repurposed drug similar to indirect competitors available in the market.
Team
We are adopting a B2B business model targeting physicians in military hospitals and directly distributing to them. Our target market strategy: concentrated marketing. Our unique value proposition: Our therapy is specifically designed & tailored for the treatment of COVID-19; It is not a repurposed drug similar to indirect competitors available in the market.
Problem Identification
We are adopting a B2B business model targeting physicians in military hospitals and directly distributing to them. Our target market strategy: concentrated marketing. Our unique value proposition: Our therapy is specifically designed & tailored for the treatment of COVID-19; It is not a repurposed drug similar to indirect competitors available in the market.
Environmental Analysis
Macroeconomic:
- Political & Legal: